The COVID-19 pandemic has provided many intensivists (and some non-intensivists) several years’ worth of severe ARDS management experience over the course of just a few months. While the challenges have, in places, been extreme, we hope that this experience will benefit future ARDS patients for years to come, even when the COVID-19 pandemic is for the history books.

The creation and success of ongoing platform trials such as RECOVERY, REMAP-CAP, and ACTIV during the pandemic will hopefully spur clinicians, patients and their families, regulators, funders, and research ethics boards to demand enrolment into randomized clinical trials, as is commonly the case in the cancer field.

Read More